Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Urethral cancer
Stage/Subtype:  proximal urethral cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-15 of 15 for your search:
Start Over
Eribulin Mesylate in Treating Patients with Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHII-75, NCI-2009-00170, CDR0000492014, 7435, CCC-PHII-75, NCI-7435, NCT00365157
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA-ALT-801-01-10, NCI-2011-03474, NCT01326871
BCG Intravesical Solution and Sunitinib Malate in Treating Patients With Bladder Cancer
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: UMCC 2008.086, NCI-2011-03616, NCT00794950
Pazopanib Hydrochloride and Paclitaxel in Treating Patients with Refractory Urothelial Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: BLDR0010, NCI-2011-00416, SU-04152010-5683, NCT01108055
Everolimus With or Without Paclitaxel as First-Line Therapy in Treating Patients Advanced Urothelial Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GU10-147, NCI-2013-00308, 1008-13, 1011004329, NCT01215136
Gemcitabine Hydrochloride, Cisplatin, and Ipilimumab as First-Line Therapy in Treating Patients With Metastatic Urothelial Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GU10-148, NCI-2013-00250, 1110007307, NCT01524991
Dose Dense Gemcitabine Hydrochloride and Cisplatin in Treating Patients with Muscle-Invasive Bladder Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-071, NCI-2012-00649, NCT01589094
Cabozantinib-S-Malate in Treating Patients with Metastatic Bladder Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-C-0205, NCI-2013-01555, 120205, 12-C-0205J, P11900, 9236, NCT01688999
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GU12-160, NCI-2013-00935, NCT01780545
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 0103-018, NCI-2014-02470, NCT02236195
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum-refractory Metastatic Bladder Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ACE-ST-005, NCI-2015-00945, NCT02351739
Gemcitabine Hydrochloride, Carboplatin, and Lenalidomide in Treating Patients with Advanced or Metastatic Urothelial Cancer or Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0140, NCI-2013-01486, 110140, NCI-2013-01426, P10742, 8876, NCT01352962
Veliparib, Paclitaxel, and Carboplatin in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 10-115, NCI-2011-02500, CDR0000700997, 8808, NCT01366144
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B2151002, NCI-2013-01814, 2013-001390-24, NCT01920061
Start Over